Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer
Dejuan Sun1, Lingjuan Zhu1, Yuqian Zhao1
1Wuya College of Innovation, School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Objectives:
Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour with poor prognosis, and the discovery of targeted small-molecule drugs for TNBC treatment still remains in its infancy. In this study, we aimed to discover a small-molecule agent for TNBC treatment and illuminate its potential mechanisms.
Materials And Methods:
Cell viability was detected by using methylthiazoltetrazolium (MTT) assay. Electron microscopy, GFP-LC3 transfection, monodansylcadaverine staining and apoptosis assay were performed to determine Fluoxetine-induced autophagy and apoptosis. Western blotting and siRNA transfection were carried out to investigate the mechanisms of Fluoxetine-induced autophagy. iTRAQ-based proteomics analysis was used to explore the underlying mechanisms.
Results:
We have demonstrated that Fluoxetine had remarkable anti-proliferative activities and induced autophagic cell death in MDA-MB-231 and MDA-MB-436 cells. The mechanism for Fluoxetine-induced autophagic cell death was associated with inhibition of eEF2K and activation of AMPK-mTOR-ULK complex axis. Further iTRAQ-based proteomics and network analyses revealed that Fluoxetine-induced mechanism was involved in BIRC6, BNIP1, SNAP29 and Bif-1.
Conclusions:
These results demonstrate that Fluoxetine induces apoptosis and autophagic cell death in TNBC, which will hold a promise for the future TNBC therapy.
Insights
Fluoxetine exhibits anti-proliferative effects against triple-negative breast cancer (TNBC) by inducing autophagic cell death. This discovery offers a promising new avenue for TNBC treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies.
- Developing novel small-molecule drugs for TNBC remains a critical unmet need.
Purpose of the Study:
- To discover a small-molecule agent for TNBC treatment.
- To elucidate the underlying mechanisms of action for potential TNBC therapeutics.
Main Methods:
- Cell viability assessed via MTT assay.
- Autophagy and apoptosis determined by electron microscopy, GFP-LC3 transfection, monodansylcadaverine staining, and apoptosis assays.
- Mechanisms investigated using Western blotting, siRNA, and iTRAQ-based proteomics.
Main Results:
- Fluoxetine demonstrated significant anti-proliferative activity in TNBC cell lines (MDA-MB-231, MDA-MB-436).
- Fluoxetine induced autophagic cell death, linked to eEF2K inhibition and AMPK-mTOR-ULK activation.
- Proteomics identified BIRC6, BNIP1, SNAP29, and Bif-1 as key players in Fluoxetine's mechanism.
Conclusions:
- Fluoxetine effectively induces apoptosis and autophagic cell death in TNBC.
- These findings suggest Fluoxetine holds promise as a future therapeutic agent for TNBC.
More Related Videos
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...


